ISA Pharmaceuticals Strengthens Patent Protection For Its Lead Product ISA101
Leiden, The Netherlands, February 24, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced it has been granted a European patent on its lead compound ISA101. The patent ensures market protection of ISA101’s active ingredient in Europe until 2028.
ISA101 is a therapeutic vaccine for the treatment of high-risk, HPV16-induced diseases. The vaccine consists of synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV16 virus. This HPV strain is responsible, among others, for over 50% of human cervical cancers, more than 85% of HPV-positive head and neck cancers, and a variety of premalignant disorders.
The patent covers long peptides of the HPV-E6 protein, including a novel CD4+ epitope and provides exclusivity for the treatment of HPV-related diseases.
“This new patent significantly strengthens our IP position,” said Ronald Loggers, ISA Pharmaceutical’s Acting Chief Executive Officer. “With market protection in Europe until 2028, we have further broadened the worldwide IP protection of our lead vaccine ISA101.”
ISA101 is currently studied in the CervISA trial, a company-sponsored Phase I/II trial in cervical cancer and anal intra-epithelial neoplasia (AIN). Moreover, the vaccine has established clinical proof-of-concept by successfully completing a Phase II trial in vulvar intraepithelial neoplasia (VIN).
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company has built a proprietary vaccine platform based on the Synthetic Long Peptide (SLP®) and AMPLIVANT® technologies, which permit the generation of safe and effective vaccines with a known mechanism of action. SLP® vaccines are broadly applicable to multiple targets and ideally suited as monotherapy or as essential components in combination with conventional cancer treatments or novel immunomodulators. As such, SLP® vaccine therapies are capable of fully harnessing and directing the body‘s own defense towards fighting the disease.
ISA101, an SLP® vaccine targeting human papillomavirus (HPV)-induced diseases, is currently in clinical development in cervical cancer and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established with ISA101 in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.
The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com
AMPLIVANT® is a registered trademark in Europe.
Contact & Media Inquiries:
akampion
Dr. Ludger Wess , Ines-Regina Buth
Managing Partner
Tel. +49 40 88 16 59 64, Tel. +49 30 23 63 27 68
info(at)akampion.com
Help employers find you! Check out all the jobs and post your resume.